There’s been a lot of grim news lately about HIV and AIDS: Rising infections among high-risk U.S. communities, continued risk behaviors, and plague-level infection rates across sub-Saharan Africa. In ...
The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...
Gilead has developed a 1-every-6-month injection to prevent HIV. The medication will sell for $14,000 a shot. With numerous proposed major cuts to Medicaid and the Affordable Care Act in congress, ...
Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV. Now, the drug will be available to those who are HIV-negative and looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback